Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
News about CVS Health Corporation (NYSE: CVS) covers developments across its roles in retail pharmacy, pharmacy benefit management, health insurance and health care delivery. Company press releases and related disclosures highlight how CVS Health communicates financial performance, strategic priorities, governance updates and community initiatives to investors, customers and the public.
Investors following CVS stock can find news on quarterly and full-year earnings announcements, financial guidance updates and Investor Day presentations. For example, CVS Health has issued press releases discussing results for specific quarters, updating full-year financial guidance and providing outlooks for future years, including projections for revenues, operating income, adjusted operating income, GAAP diluted earnings (loss) per share and adjusted EPS. These communications often appear in conjunction with Form 8-K filings that furnish the underlying press releases.
Corporate governance and leadership changes are another recurring news theme. CVS Health has announced Board decisions such as appointing its President and Chief Executive Officer, J. David Joyner, to the additional role of Chair of the Board, and it has used both press releases and Form 8-K filings to describe these actions and related Board structures.
Operational and community-focused news items describe how CVS Health engages with public health and local organizations. Examples include offering the measles-mumps-rubella (MMR) vaccine at select CVS Pharmacy and MinuteClinic locations in South Carolina during a measles outbreak, and the CVS Health Foundation’s grants to the American Diabetes Association to expand a maternal diabetes program in New York City. Other stories highlight investments in affordable housing projects and the company’s reported economic impact across U.S. states.
Visitors to this news page can review these types of announcements to understand how CVS Health presents its strategy, financial outlook, health services, community partnerships and responses to health challenges over time.
CVS (NYSE: CVS) reported Q3 2025 total revenues of $102.9B, up 7.8% year-over-year, and an adjusted EPS of $1.60. GAAP diluted loss per share was $(3.13), driven by a $5.7B goodwill impairment in the Health Care Delivery reporting unit and a $483M gain on Omnicare deconsolidation. Management raised full-year adjusted EPS guidance to $6.55–$6.65, updated GAAP EPS guidance to $(0.34)–$(0.24), and set cash flow from operations guidance to $7.5B–$8.0B. Operational highlights include industry‑leading Aetna Medicare Advantage star ratings, a nationwide vaccination campaign, and Caremark contract wins totaling nearly $6.0B.
CVS Health (NYSE: CVS) will partner with the TrumpRx Fertility program to expand access and lower costs for fertility medications. The company said CVS Specialty Pharmacy will be a core partner and offer specialist pharmacists, claims support, financial-assistance help, and next-day delivery or pickup at 9,000 CVS community pharmacies.
The announcement cites a negotiated price reduction for Gonal-F of 84% as the platform's competitive offering and states the program is expected to be available in January 2026. The company emphasized expedited pharmacy processing for time-sensitive IVF cycles and said drug participation may change before launch.
CVS (NYSE:CVS) announced completion of its acquisition of select Rite Aid and Bartell Drugs assets nationwide on Oct 15, 2025. CVS acquired 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington and 626 prescription files across 15 states, now serving more than 9 million former Rite Aid and Bartell patients.
The company hired more than 3,500 former Rite Aid and Bartell colleagues, completed the final store transfers on Sept 30, 2025, and said the U.S. Bankruptcy Court for the District of New Jersey approved the sales in May. CVS plans targeted investments, local grand-opening events, and continued availability of many local brands.
CVS Health (NYSE: CVS) released the 2025 Rx Report: Community Pharmacy Reimagined on Oct 14, 2025, reporting survey results from >2,200 consumers and >1,060 pharmacists and technicians about the future of community pharmacy.
Key findings: 77% of adults trust local pharmacists, 80% prefer face-to-face care, 75% of pharmacy professionals want expanded roles, and 40% of technicians aspire to become pharmacists. CVS says it opened nearly 100 new community locations in 2025 and operates >b>9,000 community health destinations while launching CostVantage™, a cost-based reimbursement framework with a planned 2026 transition for some government programs.
Aetna (NYSE: CVS) reported that for 2026 over 81% of its Medicare Advantage members are in plans rated 4 stars or higher by CMS, and over 63% are in 4.5-star plans. Key MA contracts and enrollments cited include H5522 (1.3M employer-group members; 4.5 stars, 14-year 4+ streak), H5521 (1.1M individual members; 4.5 stars), H3959 (210k; 4 stars), H2293 (134k; 4 stars), H1609 (132k; 4.5 stars, +0.5 star YoY), and H2663 (128k; 4 stars, 14-year 4+ streak). Ratings are based on CMS data published October 9, 2025; enrollment as of September 2025.
CVS (NYSE: CVS) opened a Workforce Innovation and Talent Center and Community Resource Center in Fort Worth on Oct. 7, 2025, in partnership with Fort Worth Housing Solutions.
The WITC offers no-cost, hands-on training for roles such as pharmacy technicians, customer service associates and call center representatives in a simulated retail environment, with graduates encouraged to apply to CVS. The CRC, supported by Aetna, will offer health education, benefits navigation, computers, teleconferencing and space for community events; health screenings are planned for late 2025.
CVS has invested $232 million+ in affordable housing across Texas, helped create or preserve nearly 14,000 housing units, invested in an 80-unit Babers Manor mixed-income residence, and awarded over $700,000 to local organizations this year.
Aetna (NYSE: CVS) has unveiled its 2026 Medicare Advantage (MA) plans, expanding access to affordable healthcare across 43 states plus Washington, D.C., reaching 57 million Medicare-eligible beneficiaries. The company will maintain $0 monthly premium plans in every service area, accessible to 82% of Medicare-eligible beneficiaries.
Key offerings include $0 copays for Tier 1 drugs, covered vaccines at in-network pharmacies, and essential preventive services. The company is expanding its Special Needs Plans, with Chronic Condition SNPs growing to 18 states and Dual Eligible SNPs expanding to 119 new counties. Members will benefit from a $2,100 annual out-of-pocket maximum for prescription drugs and access to comprehensive networks including major pharmacy chains.
BetterInvesting Magazine has selected Vertiv Holdings Co. (NYSE: VRT) as its "Stock to Study" for the December 2025 issue, highlighting the company's fundamental data including sales, earnings, pre-tax profit, and return on equity for investor analysis.
Additionally, the magazine will feature a fundamental review of CVS Health Corp. (NYSE: CVS), which the Editorial Advisory and Securities Review Committee considers potentially undervalued and worthy of further study. The committee consists of certified financial analysts and is chaired by editor Doron P. Levin.
CVS Health (NYSE: CVS) has scheduled its third quarter 2025 earnings conference call for Wednesday, October 29th, 2025, at 8:00 a.m. ET. During this call, the company will discuss its Q3 2025 financial performance with analysts and investors.
The event will be accessible through an audio webcast on the Investor Relations section of CVS Health's website at investors.cvshealth.com. The webcast recording will remain available for replay on the website for one year following the event.
Omnicare, a subsidiary of CVS Health (NYSE: CVS), has initiated voluntary Chapter 11 bankruptcy proceedings in response to litigation challenges and industry-wide financial pressures. The company has secured $110 million in debtor-in-possession financing to maintain operations during the restructuring process.
The bankruptcy filing follows a court ruling in the U.S. District Court for the Southern District of New York regarding alleged technical violations of pharmacy law. Omnicare plans to use this process to evaluate restructuring options, including a potential standalone restructuring or sale strategy. The company emphasizes that it will continue providing uninterrupted pharmacy services to long-term care facilities and maintain regular business operations, including employee wages and vendor payments.